TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial   

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Medtronic; Recor Medical; Ablative Solutions
• Grant Support/Research Contract (Institutional) - Ablative Solutions; Medtronic; Recor